Survival outcomes for patients with multiple myeloma in France: A retrospective cohort study using the Système National des Données de Santé national healthcare database

Abstract

AbstractObjectiveEvaluate the overall survival (OS) of patients with multiple myeloma (MM) at different treatment stages in France.MethodsThis retrospective observational cohort study used data from the French National Health Insurance database to study patients with MM (diagnosis 2013–2019). Patient outcomes included OS (all‐cause mortality), time‐to‐next treatment (TTNT), and duration of therapy (DoT) from initial diagnosis, the start of different lines of therapy (LOTs), triple‐class exposure (TCE), and subsequent treatment following TCE. The Kaplan–Meier method analyzed “time‐to‐event” data.ResultsFrom diagnosis, death rates increased from 1% at 1 month to 24% at 2 years; median OS was 63.8 months (N = 14 309). Median OS from the start of LOTs declined from 61.0 months (LOT1) to 14.8 months (LOT4). Median OS from TCE start was 14.7 months. There was a large variation in TTNT within LOTs (e.g., LOT1: bortezomib + lenalidomide: TTNT = 26.4 months, OS = 61.7 months; lenalidomide: TTNT = 20.0 months, OS = 39.6 months); DoT was similar for LOT1 and LOT2, then progressively declined at LOT4. Patients with stem cell transplant, younger age, and less comorbidity had better survival outcomes.ConclusionsPatients with MM face a poor prognosis after relapse to multiple LOTs and TCE, demonstrating a worsening of survival outcomes. Access to novel therapies may improve outcomes.